Global Antibiotic R&D Partnership (GARDP)
Alan Hennessy currently serves as the Discovery and Exploratory Research Team Lead at the Global Antibiotic R&D Partnership (GARDP) since June 2023. Prior to this role, Alan Hennessy held various leadership positions at Syngenta from March 2011 to June 2023, including Group Leader and Head of Lead Generation, where responsibilities encompassed oversight of lead generation efforts. Alan Hennessy's earlier experience at GSK from November 2001 to March 2011 involved management of medicinal chemistry teams focused on antibacterial research, including the invention of Gepotidacin, which is in Phase III clinical trials. Academic qualifications include a PostDoc in Organic Synthesis from Imperial College London and a PhD in Asymmetric Catalysis from University College Dublin, where Alan Hennessy also earned a BSc (Hons) in Chemistry.
This person is not in any offices
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org